Core Insights - Edwards Lifesciences announced seven-year data from the PARTNER 3 trial, highlighting early and sustained patient benefits from its TAVR technology [1] - The data demonstrated superior clinical outcomes at one year, along with excellent long-term valve performance and durability [1] - Additionally, ten-year results from PARTNER 2 intermediate risk studies further reinforce Edwards' leadership in establishing standards for lasting valve performance and patient outcomes [1]